Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan Inc) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis PLC markets brand products through six franchises in key therapeutic categories including:
- Aesthetics/Dermatology/Plastic Surgery;
- Neurosciences/CNS;
- Eye Care;
- Women's Health and Urology;
- GI and Cystic Fibrosis; and
- Cardiovascular Disease and Infectious Disease.
The company's products include:
- Botox, Namenda,
- Restasis,
- Linzess,
- Bystolic,
- Juvederm,
- Latisse,
- Lo Loestrin Fe,
- Estrace,
- Teflaro,
- Dalvance,
- Ozurdex,
- Optive,
- Natrelle,
- Viibryd,
- Liletta,
- Saphris,
- Enablex,
- Actonel,
- Androderm,
- Gelnique
- Others.
Actavis PLC also operates the world's third-largest generics business. The company has been ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.
Actavis also develops and out-licenses generic pharmaceutical products outside the US through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers more than 200 products.
Actavis PLC is also developing biosimilars products in oncology and other therapeutic categories, and currently has five biosimilar products in development.
Actavis PLC has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also included Anda Inc, the fourth-largest US generic pharmaceutical product distributor in the United States.
On June 15, 2015, Actavis plc changed its name to Allergan plc, but the company's U.S. and Canadian generics business will continue to operate under the Actavis name.
In July 2015, Allergan PLC announced it would sell its Generics division of the company, including Anda Inc, to Teva Pharmaceuticals for $40.5 billion, a transaction proposed for completion by the first quarter of 2016.
Actavis PLC has 27 global R&D facilities focusing on the development of modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables around the world. The company's R&D facilities are located in Belgium, Bulgaria, China, France, Iceland, Italy, India, Indonesia, Ireland, Japan, Romania, the UK and the US.